8/7/2019 1:14:23 AM
Obseva Posts Q2 Loss Per Share Of $0.80; Announces $75 Mln Credit Facility With Oxford Finance
7/18/2019 7:52:24 AM
Wedbush Reiterates ObsEva SA (OBSV) At Outperform With $38 Price Target
7/8/2019 1:15:14 AM
ObsEva SA Announces Completion Of Patient Recruitment In PRIMROSE 1 Phase 3 Clinical Trial Of Linzagolix
7/1/2019 1:56:01 AM
ObsEva Appoints Elizabeth Garner As Chief Medical Officer And Member Of Executive Committee, Effective July 15
6/19/2019 5:02:19 PM
Wedbush Reiterates ObsEva SA (OBSV) At Outperform With $38 Price Target
6/19/2019 1:04:32 AM
ObsEva Progressing Toward U.S. Phase 3 Trial For Nolasiban In IVF Following Recent FDA Meeting
6/4/2019 1:01:47 AM
ObsEva SA Announces Completion Of Patient Recruitment In IMPLANT 4 Phase 3 Clinical Trial Of Nolasiban
11/28/2018 1:04:43 AM
ObsEva Begins Phase 3 IMPLANT 4 Trial Of Nolasiban In Europe, Canada And Russia For Improving IVF Outcomes
11/8/2018 1:46:09 AM
ObsEva Q3 Net Loss $18.6 Mln Or $0.42/Shr Vs $17.0 Mln Or $0.59/Shr Last Year
10/5/2018 1:02:28 AM
ObsEva SA Announces Phase 3 IMPLANT 2 Clinical Trial Results Of Nolasiban In IVF
10/3/2018 1:01:59 AM
ObsEva Reports Addl Positive Phase 3 Results Of IMPLANT 2 Trial
9/28/2018 1:01:46 AM
ObsEva Reports Additional Positive Results From EDELWEISS Clinical Trial Of Oral GnRH Receptor Antagonist, Linzagolix
8/8/2018 1:04:30 AM
ObsEva Q2 Net Loss $18.2 Mln Or $0.49/Shr Vs Loss $17.3 Mln Or $0.61/Shr Last Year
8/6/2018 7:27:01 PM
Wedbush Initiates ObsEva SA (OBSV) At Outperform With $34.00 Price Target
7/25/2018 1:42:23 AM
ObsEva Names Wim Souverijns Chief Commercial Officer
7/13/2018 1:32:28 AM
ObsEva SA To Start Trading Today On The SIX Swiss Exchange Under The Ticker Symbol 'OBSN'
7/6/2018 1:34:26 AM
ObsEva Therapies In Development Reaching Clinical Milestones In 2018 And Confirmation Of Potential Therapeutic Benefits